Healthcare facilities need to provide the best possible care and outcomes for patients with COVID-19. To do this and truly protect patients not just from the risks associated with the initial COVID-19 infection but also with bacterial co-infections acquired within the healthcare system, hospitals should consider simultaneously incorporating broader testing for bacterial co-infections that can be acquired during a patient’s hospital stay. The solutions are readily available, FDA-cleared and easily integrated in the form of PCR, for lower respiratory specimens, LRT aspirate and BAL panels, and diagnostic technologies that quickly analyze pathogens and identify bacterial co-infections.
About the author: Oliver Schacht is the CEO of OpGen.Back to HCB News
Ad Statistics
Times Displayed: 43426
Times Visited: 1280 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
